Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning

The article found some significantly mutated genes in CC using NGS technology and predicted that 55.9% of CC patients might potentially benefit from targeted drugs. And HPV integrations occurred in 97.8% of the CCs, 70.5% of the CINs and 42.8% normal cervical samples with HPV infection. Integrations of high-risk HPV strains in CCs, including HPV16, 18, 33 and 58, also occurred in the CIN samples. Moreover, gene mutations were detected in 52% of CIN specimens. This article provide a strong evidence of the molecular events may serve as potential biomarker for cervical cancer screening and treatment. (By Dr Jian Huang, https://jmg.bmj.com/content/early/2018/12/19/jmedgenet-2018-105745 )

(Visited 98 times, 1 visits today)